Controversies in COX-2 inhibitor therapy: closing remarks.
Explore the source record for details and available documents.
Analgesics↗
Biomedical subjects
D E Furst
Publications and source records attributed to D E Furst.
Metabolism of meseclazone in man.
Explore the source record for details and available documents.
Benzoxazines↗
Pulmonary disease in systemic lupus erythematosus.
Pulmonary problems are common in systemic lupus erythematosus, and may be the presenting feature of this multi-system disease. The clinical spectrum ranges from mild, self-limited, pleuritic chest pain to fulminant and rapidly fatal, diffuse, pulmonary hemorrhage. Accordingly, treatment must be individually tailored to the clinical features of each patient. Non-steroidal-anti-inflammatory drugs may be adequate therapy for pleuritic pain. High dose corticosteroids may be indicated in more severe cases of pleurisy with effusion, lupus pneumonitis, and diffuse interstitial lung disease. Immunosuppressive drugs such as azathioprine and cyclophosphamide should be considered in cases of lupus pneumonitis or interstitial lung disease unresponsive to steroids. Combined therapy with corticosteroids, immunosuppressives and plasmapheresis should be considered for fulminant cases of diffuse pulmonary hemorrhage attributed to lupus. There is no definitive therapy for pulmonary hypertension at this time. Decisions regarding treatment in each instance must be made with the recognition that there is little strong clinical evidence to support the use of any of these therapies. Finally, no pulmonary process should be attributed to lupus until infection has been rigorously excluded in these patients.
Adrenal Cortex Hormones↗
Single dose pharmacokinetics of auranofin in rheumatoid arthritis.
Six rheumatoid arthritis (RA) patients were given 2 6 mg doses of auranofin (AF) containing Au195, 6 months apart. The radioactivity in the whole body and in plasma, urine, and stool samples was measured for 6 months after each dose. Absorption was rapid with peak plasma concentrations occurring 1.2-2 h post administration. 195Au plasma half-lives (t1/2) ranged from 11.0-31.3 days, with 195Au detectable in plasma for about 80 days. Total body t1/2 averaged 69.2+/-29.7 days. Urinary excretion accounted for 15% of the dose. Cumulative stool excretion was 89%, although 72% was excreted in 10 days. Continued stool excretion over 6 months suggested a "central-enteric" component to the excretory route.
Absorption↗
Case report: progressive systemic sclerosis-like syndrome after bone marrow transplantation. Clinical, immunologic, and pathologic findings.
A young man developed chronic graft-versus-host disease (GvHD) after allogeneic bone marrow transplantation. The close resemblance of his skin changes to those of patients with progressive systemic sclerosis (PSS) prompted an examination for clinical and pathologic involvement of other organ systems. Many of the dermatologic, cardiac, renal and pulmonary findings in the transplant patient were similar to those seen in a comparison group of 38 patients with PSS.
Adolescent↗
From disease modification to disease control in rheumatoid arthritis.
In the development of therapies to treat rheumatoid arthritis, measurement of response is essential. Such measurement has incrementally advanced from symptom modification through radiological improvement to a requirement for change in inflammation, change in function, and the prevention of further structural damage.
Antirheumatic Agents↗